Histatin for corneal wound healing and ocular surface disease

Abstract

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

What is claimed is: 
     
         1 . A method of treating ocular surface disease, comprising the step of continually administering a therapeutic amount of a composition through incorporation of the composition into a contact lens worn by a patient, the composition comprising a first peptide and a second peptide to an ocular surface, wherein the first peptide comprises a first histatin or a fragment of the first histatin and the second peptide comprises a second histatin or a fragment of the second histatin;
 wherein the therapeutic amount of the composition is selected such that the composition accelerates healing of ocular surface disease compared to healing of ocular surface disease not treated with the composition;   wherein an amino acid sequence of each of the first peptide and the second peptide is selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; and any combination of SEQ ID NO: 1 through SEQ ID NO: 33;   wherein the first peptide comprises histatin 1 or a fragment of histatin 1; and   wherein the second peptide comprises histatin 5 or a fragment of histatin 5.   
     
     
         2 . The method of  claim 1 , wherein the first peptide further comprises histatin 2 or a fragment of histatin 2. 
     
     
         3 . The method of  claim 1 , wherein the method treats humans. 
     
     
         4 . The method of  claim 1 , wherein the concentration of each of the first peptide and the second peptide in the composition is between approximately 0.1 μg/ml and approximately 1000 mg/ml. 
     
     
         5 . The method of  claim 4 , wherein the concentration of each of the first peptide and the second peptide in the composition is between approximately 0.1 μg/ml and 10 μg/ml. 
     
     
         6 . The method of  claim 1 , further comprising repeating the step of administering the therapeutic amount of the composition to the ocular surface at least one time per day for a plurality of days. 
     
     
         7 . The method of  claim 1 , further comprising chronically repeating the step of administering the therapeutic amount of the composition to the ocular surface at least one time a day. 
     
     
         8 . The method of  claim 1 , wherein the amino acid sequence of the second peptide is selected from the group consisting of SEQ ID NO: 30 and SEQ ID NO: 31. 
     
     
         9 . The method of  claim 1 , wherein the amino acid sequence of the first peptide is selected from the group consisting of SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 29; and SEQ ID NO: 33. 
     
     
         10 . The method of  claim 2 , wherein the amino acid sequence of the first peptide is selected from the group consisting of SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 13; SEQ ID NO: 29; and SEQ ID NO: 33. 
     
     
         11 . The method of  claim 1 , wherein the ocular surface disease is selected from the group consisting of dry eyes, corneal ulcerations and erosions, inflammatory and infectious keratitis and conjunctivitis, surgical interventions, and trauma. 
     
     
         12 . The method of  claim 1 , wherein the first peptide and the second peptide are 8 to 44 amino acids in length. 
     
     
         13 . The method of  claim 1 , wherein the first peptide and the second peptide are L-peptides. 
     
     
         14 . The method of  claim 1 , wherein the first peptide is a cyclic peptide. 
     
     
         15 . The method of  claim 14 , wherein the first peptide comprises SEQ ID NO: 33. 
     
     
         16 . The method of  claim 1 , wherein the first peptide comprises SEQ ID NO: 33. 
     
     
         17 . A method of treating ocular surface disease, comprising the step of continually administering a therapeutic amount of a composition using eye drops gels, ointments or tissue glue, the composition comprising a first peptide and a second peptide to an ocular surface, wherein the first peptide comprises a first histatin or a fragment of the first histatin and the second peptide comprises a second histatin or a fragment of the second histatin;
 wherein the therapeutic amount of the composition is selected such that the composition accelerates healing of ocular surface disease compared to ocular surface disease not treated with the composition;   wherein an amino acid sequence of each of the first peptide and the second peptide is selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; and any combination of SEQ ID NO: 1 through SEQ ID NO: 33;   wherein the first peptide comprises histatin 1 or a fragment of histatin 1; and   wherein the second peptide comprises histatin 5 or a fragment of histatin 5.   
     
     
         18 . The method of  claim 17 , further comprising repeating the step of administering the therapeutic amount of the composition to the ocular surface at least one time per day for a plurality of days. 
     
     
         19 . The method of  claim 17 , further comprising chronically repeating the step of administering the therapeutic amount of the composition to the ocular surface at least one time per day. 
     
     
         20 . The method of  claim 17 , further comprising repeating the step of administering the therapeutic amount of the composition to the ocular surface up to hourly for a plurality of days.